Developer docs
API playgroundTry for free, no card

Search company profiles

OCCIDENT

Full company profile

uuid0006nam

Namestring
OCCIDENT
Legal namestring
Occident Ventures GmbH
Websiteurl
occident.group
Company typeenum
Private
Founded yearint
2012
Descriptiontext

OCCIDENT (legal name: Occident Ventures GmbH) is an owner-managed venture capital firm founded in 2012 by Patrizia Schützenhöfer (CEO) and Michael Pauer (CIO), headquartered in Munich, Germany with a secondary office in Zug, Switzerland. The firm operates with a deliberately compact team of four — CEO, CIO, Senior Investment Manager for Life Sciences, and Junior Investment Manager — and invests its own capital, not external limited-partner funds, alongside co-investors in deep-tech startups. Its stated thesis is to fund spin-offs derived from scientific research that can generate sustainable societal impact, with a focus on the DACH region.

The firm's investment approach centers on Seed and Series A rounds with typical initial ticket sizes of €500,000 to €1,000,000, plus follow-on participation in subsequent rounds. Deal sourcing is driven by the proprietary OCCIDENT@ACADEMIA program, which formalizes partnerships with twelve-plus academic and research-institution partners including Max Planck Innovation, Helmholtz Association, TUM Venture Lab Healthcare, BioM, BioRN, SPRIND, University Hospital Zurich's Health Innovation Hub, and others. The active portfolio spans 14 companies across life sciences (biotech, pharma, diagnostics, MedTech, HealthTech, veterinary medicine, chemistry, FoodTech, industrial biotech) and industrial tech (sensors, semiconductors, advanced materials, software testing), with named holdings including Tubulis, Lymphatica Medtech, hemotune, InSphero, Resistell, Lunaphore, Code Intelligence, and core-sensing.

OCCIDENT generates returns exclusively through equity realizations on portfolio exits, with no management fees or external fund economics. The firm has recorded seven successful exits, the landmark being the April 2026 sale of portfolio company Tubulis to Gilead Sciences for $3.15 billion plus up to $1.85 billion in milestone payments — the largest transaction in OCCIDENT's history. Other exits include adivo (to Zoetis), Lunaphore (to Bio-Techne), and Versantis (to GENFIT). OCCIDENT develops no proprietary technology itself; its value proposition is fundamentally financial and relational — providing early-stage capital and active portfolio support to scientific founders in the DACH region.

Short descriptiontext

OCCIDENT is a Munich-based, owner-managed venture capital firm investing its own capital in deep-tech life sciences and industrial tech spin-offs from scientific research across the DACH region, with 14 active portfolio companies and 7 exits including Tubulis's $3.15B sale to Gilead.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMünchen, Germany
HQ citystring
München
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, deep tech startups, life sciences investment, seed stage funding, university spin offs
Industry1 code
PRIMARYFSANAHAL
Corporate Deep Tech / R&D Commercialization CVC
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

OCCIDENT generates returns through equity investments in deep tech startups. They invest their own capital alongside co-investors and earn returns upon successful exits of portfolio companies. Notable exits include Tubulis (sold to Gilead for $3.15B plus up to $1.85B in milestones), adivo (sold to Zoetis), and Lunaphore (sold to Bio-Techne).

occident.group
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

OCCIDENT is an owner-managed venture capital firm that invests its own capital into deep-tech startups, beginning at the Seed financing round and continuing with follow-on investments through Series A and later rounds. The firm focuses on scientific research spin-offs across life sciences (Biotech, Pharma, Diagnostics, MedTech, HealthTech, Veterinary Medicine, Chemistry, FoodTech, Industrial Biotech) and industrial tech (semiconductors, sensors, advanced materials). In addition to capital, OCCIDENT provides active portfolio management and acts as a long-term partner to founders, leveraging its OCCIDENT@ACADEMIA program for deal sourcing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 7 successful exits including Tubulis ($3.15B exit to Gilead)
+2 more records
Product overview1 text field

OCCIDENT is a Munich-based venture capital firm (The Science Investor) that provides investment services to deep-tech startups, particularly spin-offs from scientific research. Their offering consists of financial investment from Seed through Series A and follow-on rounds, combined with entrepreneurial support and strategic guidance. They invest their own capital with a focus on sustainable success potential. OCCIDENT's portfolio spans 14 active portfolio companies and 7 successful exits across life sciences, industrial tech, and digital sectors. Their investment focus areas include Biotech, Pharma, Diagnostics, MedTech, HealthTech, Veterinary Medicine, Chemistry, FoodTech, and Industrial Biotech.

Product and service4 records
1Seed-stage equity financing
CategoryVenture Capital Financing
Description

Equity investments of typically €500,000–€1,000,000 into deep-tech startups originating from scientific research, supporting the earliest stages of company formation from academic spin-offs. Targeted at founding teams seeking initial venture capital to advance scientific innovations toward market readiness in life sciences and industrial tech.

2Series A equity financing
CategoryVenture Capital Financing
Description

Equity participation in Series A financing rounds of deep-tech portfolio companies, scaling up investments in subsequent rounds alongside co-investors. Targeted at venture-ready deep-tech companies seeking growth capital beyond Seed.

3Follow-on equity financing
CategoryVenture Capital Financing
Description

Continued equity participation in subsequent financing rounds (Series B, Series C, and later) of portfolio companies to support their continued growth. Targeted at existing OCCIDENT portfolio companies advancing toward later-stage clinical or commercial milestones.

4OCCIDENT@ACADEMIA program
CategoryAcademic Spin-off Sourcing and Support
Description

Structured partnership program with universities, research institutions, biotech clusters, and technology-transfer offices for sourcing and supporting academic spin-offs. Targeted at research institutions, universities, and founders seeking access to OCCIDENT's venture capital and expertise for commercializing scientific research.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership22 partners
Strategic tierOption And License AgreementTypeStrategic or Co-development PartnerAnnounced on2023-04-20
Description

Tubulis entered into an option and license agreement with Gilead Sciences valued at up to $415 million to advance ADC treatment for solid tumors.

Strategic tierStrategic PartnershipTypeStrategic or Co-development PartnerAnnounced on2023-04-17
Description

Lunaphore, an OCCIDENT portfolio company, entered a strategic partnership with Bio-Techne to develop a fully automated spatial multiomics workflow.

Strategic tierStrategic CollaborationTypeStrategic or Co-development PartnerAnnounced on2023-03-23
Description

hemotune, an OCCIDENT portfolio company, entered a feasibility project with AstraZeneca for its HemoSystem blood purification platform technology.

4Lymphatica Medtech
Strategic tierPortfolio CompanyTypeStrategic or Co-development Partner
Description

OCCIDENT participated in Lymphatica's €17.9 million Series B funding round. Lymphatica develops implantable medical devices for lymphedema treatment.

occident.group
5CRISP (Center for Research and Innovation in Clinical Pharmaceutical Sciences)
Strategic tierResearch CollaborationTypeStrategic or Co-development Partner
Description

Resistell, an OCCIDENT portfolio company, collaborated with CRISP at CHUV Lausanne to combat multi-resistant bacterial lung infections.

occident.group
6Bristol Myers Squibb
Strategic tierLicensing AgreementTypeStrategic or Co-development Partner
Description

Tubulis entered a strategic licensing agreement with Bristol Myers Squibb for the development of next-generation ultra-stable antibody-drug conjugates (ADCs).

occident.group
Strategic tierResearch CollaborationTypeStrategic or Co-development Partner
Description

Resistell started a research project with Pfizer to establish pre-clinical proof of concept for antibiotic susceptibility testing.

8Occident Ventures GmbH
Strategic tierLegal EntityTypeOthers
Description

The official legal entity name of OCCIDENT is Occident Ventures GmbH, located at Klenzestr. 22, 80469 Munich.

occident.group
Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT collaborates with the German Helmholtz Association through the OCCIDENT@ACADEMIA program to identify and support promising academic spin-offs. OCCIDENT serves on the Helmholtz Enterprise Jury.

Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT partners with xista science ventures to co-organize pitch events and identify promising deep tech startups from academic backgrounds.

11CO-OPERAID
Strategic tierCsr PartnershipTypeOthers
Description

OCCIDENT supports the CO-OPERAID Talents project, a scholarship program for youth from poor families in Bangladesh, Cambodia, and Laos. OCCIDENT has supported this initiative for over 10 years, helping 54 students access higher education.

occident.group
Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - supports spin-offs from University of Basel.

Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - supports biotech spin-offs in the BioindustryPark ecosystem.

Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - Munich biotech cluster network supporting spin-offs.

Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - Rhine-Neckar biotech cluster supporting academic spin-offs.

16Gateway to Köln
Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - Cologne startup gateway supporting academic commercialization.

occident.group
Strategic tierKey Academic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - technology transfer organization for Max Planck Society, a key source of deep tech spin-offs.

18National Institute of Chemistry (Slovenia)
Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - supports spin-offs from the National Institute of Chemistry in Ljubljana.

occident.group
Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - supports deep tech startups through Germany's SPRIND innovation agency.

Strategic tierKey Academic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - supports spin-offs from Technical University of Munich's healthcare vertical.

Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - supports spin-offs from USI in southern Switzerland.

Strategic tierAcademic PartnerTypeStrategic or Co-development Partner
Description

OCCIDENT@ACADEMIA partner - supports healthcare spin-offs from USZ.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German federal seed/early-stage VC focused on deep tech and life sciences, co-investor with OCCIDENT in Tubulis. Directly comparable in geography, ticket size, and academic-spin-off sourcing model.

TypeDirect peer
Description

Cologne-based German VC investing Seed-to-Series A in technology-enabled and life sciences startups. Co-invested with OCCIDENT in Tubulis Series B, sharing similar initial ticket sizes and DACH focus.

TypeDirect peer
Description

Bavarian state-backed VC fund providing Seed to later-stage capital to technology and life sciences startups in the OCCIDENT home region. Existing co-investor in Tubulis Series C rounds.

TypeBroad incumbent
Description

Paris-based private equity and venture investor with a sizeable European life sciences franchise. Led Tubulis Series B (€60M) — directly overlapping OCCIDENT in life sciences deal underwriting at scale.

TypeDirect peer
Description

Leading European life sciences specialist VC with deep biotech focus across multiple therapeutic areas. Comparable in thesis (science-driven biotech investing) but operates at significantly larger AUM.

6EQT Life Sciences
TypeBroad incumbent
Description

Pan-European life sciences investor (formerly LSP), writing Series A through growth cheques. Co-invested with OCCIDENT in Tubulis Series C, overlapping in late-stage biotech deal participation.

TypeDirect peer
Description

Austrian-based deep tech and science-focused VC co-organizing pitch events with OCCIDENT. Closest scale and thesis match — both focus on academic spin-offs in DACH.

TypeBroad incumbent
Description

Paris-based European VC with strong life sciences/healthcare franchise. Co-investor in Tubulis Series C, comparable in cross-stage European biotech investing but with larger fund management structure.

TypeDirect peer
Description

Swiss/German-based VC investing in life sciences and biotech companies. Co-invested with OCCIDENT in Tubulis Series B — comparable academic-spin-out pipeline and DACH geography.

TypeBroad incumbent
Description

Large drug-discovery and development platform with an active VC/strategic partnership arm. Co-invested in Tubulis Series B and directly overlaps with OCCIDENT portfolio in early-stage biotech deal participation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment38 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OCCIDENT

Venture Capitaloccident.group

OCCIDENT is a Munich-based, owner-managed venture capital firm investing its own capital in deep-tech life sciences and industrial tech spin-offs from scientific research across the DACH region, with 14 active portfolio companies and 7 exits including Tubulis's $3.15B sale to Gilead.

What OCCIDENT does

OCCIDENT (legal name: Occident Ventures GmbH) is an owner-managed venture capital firm founded in 2012 by Patrizia Schützenhöfer (CEO) and Michael Pauer (CIO), headquartered in Munich, Germany with a secondary office in Zug, Switzerland. The firm operates with a deliberately compact team of four — CEO, CIO, Senior Investment Manager for Life Sciences, and Junior Investment Manager — and invests its own capital, not external limited-partner funds, alongside co-investors in deep-tech startups. Its stated thesis is to fund spin-offs derived from scientific research that can generate sustainable societal impact, with a focus on the DACH region.

The firm's investment approach centers on Seed and Series A rounds with typical initial ticket sizes of €500,000 to €1,000,000, plus follow-on participation in subsequent rounds. Deal sourcing is driven by the proprietary OCCIDENT@ACADEMIA program, which formalizes partnerships with twelve-plus academic and research-institution partners including Max Planck Innovation, Helmholtz Association, TUM Venture Lab Healthcare, BioM, BioRN, SPRIND, University Hospital Zurich's Health Innovation Hub, and others. The active portfolio spans 14 companies across life sciences (biotech, pharma, diagnostics, MedTech, HealthTech, veterinary medicine, chemistry, FoodTech, industrial biotech) and industrial tech (sensors, semiconductors, advanced materials, software testing), with named holdings including Tubulis, Lymphatica Medtech, hemotune, InSphero, Resistell, Lunaphore, Code Intelligence, and core-sensing.

OCCIDENT generates returns exclusively through equity realizations on portfolio exits, with no management fees or external fund economics. The firm has recorded seven successful exits, the landmark being the April 2026 sale of portfolio company Tubulis to Gilead Sciences for $3.15 billion plus up to $1.85 billion in milestone payments — the largest transaction in OCCIDENT's history. Other exits include adivo (to Zoetis), Lunaphore (to Bio-Techne), and Versantis (to GENFIT). OCCIDENT develops no proprietary technology itself; its value proposition is fundamentally financial and relational — providing early-stage capital and active portfolio support to scientific founders in the DACH region.

OCCIDENT firmographics

Firmographics
Name
OCCIDENT
Legal name
Occident Ventures GmbH
Website
https://occident.group
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
OCCIDENT is a Munich-based, owner-managed venture capital firm investing its own capital in deep-tech life sciences and industrial tech spin-offs from scientific research across the DACH region, with 14 active portfolio companies and 7 exits including Tubulis's $3.15B sale to Gilead.
Ownership category
akta.pro rank

OCCIDENT industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAL
Corporate Deep Tech / R&D Commercialization CVC

Keywords

  • Venture capital investing
  • Deep tech startups
  • Life sciences investment
  • Seed stage funding
  • University spin offs

Where OCCIDENT is headquartered

Location

Headquarters

HQ city
München
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

OCCIDENT business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Venture Capital Returns: OCCIDENT generates returns through equity investments in deep tech startups. They invest their own capital alongside co-investors and earn returns upon successful exits of portfolio companies. Notable exits include Tubulis (sold to Gilead for $3.15B plus up to $1.85B in milestones), adivo (sold to Zoetis), and Lunaphore (sold to Bio-Techne).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

OCCIDENT product offering

Product offering

Core offering

OCCIDENT is an owner-managed venture capital firm that invests its own capital into deep-tech startups, beginning at the Seed financing round and continuing with follow-on investments through Series A and later rounds. The firm focuses on scientific research spin-offs across life sciences (Biotech, Pharma, Diagnostics, MedTech, HealthTech, Veterinary Medicine, Chemistry, FoodTech, Industrial Biotech) and industrial tech (semiconductors, sensors, advanced materials). In addition to capital, OCCIDENT provides active portfolio management and acts as a long-term partner to founders, leveraging its OCCIDENT@ACADEMIA program for deal sourcing.

Product overview

OCCIDENT is a Munich-based venture capital firm (The Science Investor) that provides investment services to deep-tech startups, particularly spin-offs from scientific research. Their offering consists of financial investment from Seed through Series A and follow-on rounds, combined with entrepreneurial support and strategic guidance. They invest their own capital with a focus on sustainable success potential. OCCIDENT's portfolio spans 14 active portfolio companies and 7 successful exits across life sciences, industrial tech, and digital sectors. Their investment focus areas include Biotech, Pharma, Diagnostics, MedTech, HealthTech, Veterinary Medicine, Chemistry, FoodTech, and Industrial Biotech.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seed-stage equity financing Equity investments of typically €500,000–€1,000,000 into deep-tech startups originating from scientific research, supporting the earliest stages of company formation from academic spin-offs. Targeted at founding teams seeking initial venture capital to advance scientific innovations toward market readiness in life sciences and industrial tech.
  • Series A equity financing Equity participation in Series A financing rounds of deep-tech portfolio companies, scaling up investments in subsequent rounds alongside co-investors. Targeted at venture-ready deep-tech companies seeking growth capital beyond Seed.
  • Follow-on equity financing Continued equity participation in subsequent financing rounds (Series B, Series C, and later) of portfolio companies to support their continued growth. Targeted at existing OCCIDENT portfolio companies advancing toward later-stage clinical or commercial milestones.
  • OCCIDENT@ACADEMIA program Structured partnership program with universities, research institutions, biotech clusters, and technology-transfer offices for sourcing and supporting academic spin-offs. Targeted at research institutions, universities, and founders seeking access to OCCIDENT's venture capital and expertise for commercializing scientific research.

Quantifiable outcome

  • 7 successful exits including Tubulis ($3.15B exit to Gilead)
  • +2 more outcomes

Companies that use OCCIDENT

Customer profile

Segments2 records

Ideal customer profiles2 records

OCCIDENT technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OCCIDENT partnerships and signals

Strategic signal

Partnerships

22 partnerships are on record, tiered option and license agreement, strategic partnership, strategic collaboration, portfolio company, research collaboration, licensing agreement, legal entity, academic partner, csr partnership and key academic partner.

  • Gilead Sciencesoption and license agreementStrategic or Co-development Partner · 20 April 2023Tubulis entered into an option and license agreement with Gilead Sciences valued at up to $415 million to advance ADC treatment for solid tumors.
  • Bio-Technestrategic partnershipStrategic or Co-development Partner · 17 April 2023Lunaphore, an OCCIDENT portfolio company, entered a strategic partnership with Bio-Techne to develop a fully automated spatial multiomics workflow.
  • AstraZenecastrategic collaborationStrategic or Co-development Partner · 23 March 2023hemotune, an OCCIDENT portfolio company, entered a feasibility project with AstraZeneca for its HemoSystem blood purification platform technology.
  • Lymphatica Medtechportfolio companyStrategic or Co-development PartnerOCCIDENT participated in Lymphatica's €17.9 million Series B funding round. Lymphatica develops implantable medical devices for lymphedema treatment.
  • CRISP (Center for Research and Innovation in Clinical Pharmaceutical Sciences)research collaborationStrategic or Co-development PartnerResistell, an OCCIDENT portfolio company, collaborated with CRISP at CHUV Lausanne to combat multi-resistant bacterial lung infections.
  • Bristol Myers Squibblicensing agreementStrategic or Co-development PartnerTubulis entered a strategic licensing agreement with Bristol Myers Squibb for the development of next-generation ultra-stable antibody-drug conjugates (ADCs).
  • Pfizerresearch collaborationStrategic or Co-development PartnerResistell started a research project with Pfizer to establish pre-clinical proof of concept for antibiotic susceptibility testing.
  • Occident Ventures GmbHlegal entityOthersThe official legal entity name of OCCIDENT is Occident Ventures GmbH, located at Klenzestr. 22, 80469 Munich.
  • Helmholtz Associationacademic partnerStrategic or Co-development PartnerOCCIDENT collaborates with the German Helmholtz Association through the OCCIDENT@ACADEMIA program to identify and support promising academic spin-offs. OCCIDENT serves on the Helmholtz Enterprise Jury.
  • xista science venturesacademic partnerStrategic or Co-development PartnerOCCIDENT partners with xista science ventures to co-organize pitch events and identify promising deep tech startups from academic backgrounds.
  • CO-OPERAIDcsr partnershipOthersOCCIDENT supports the CO-OPERAID Talents project, a scholarship program for youth from poor families in Bangladesh, Cambodia, and Laos. OCCIDENT has supported this initiative for over 10 years, helping 54 students access higher education.
  • University of Basel Innovation Officeacademic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - supports spin-offs from University of Basel.
  • BioindustryParkacademic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - supports biotech spin-offs in the BioindustryPark ecosystem.
  • BioMacademic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - Munich biotech cluster network supporting spin-offs.
  • BioRNacademic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - Rhine-Neckar biotech cluster supporting academic spin-offs.
  • Gateway to Kölnacademic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - Cologne startup gateway supporting academic commercialization.
  • Max Planck Innovationkey academic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - technology transfer organization for Max Planck Society, a key source of deep tech spin-offs.
  • National Institute of Chemistry (Slovenia)academic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - supports spin-offs from the National Institute of Chemistry in Ljubljana.
  • SPRINDacademic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - supports deep tech startups through Germany's SPRIND innovation agency.
  • TUM Venture Lab Healthcarekey academic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - supports spin-offs from Technical University of Munich's healthcare vertical.
  • USI (Università della Svizzera Italiana)academic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - supports spin-offs from USI in southern Switzerland.
  • University Hospital Zurich (USZ) Health Innovation Hubacademic partnerStrategic or Co-development PartnerOCCIDENT@ACADEMIA partner - supports healthcare spin-offs from USZ.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

OCCIDENT competitors and assessment

Company assessment

Direct peers

  • High-Tech Gründerfonds (HTGF): German federal seed/early-stage VC focused on deep tech and life sciences, co-investor with OCCIDENT in Tubulis. Directly comparable in geography, ticket size, and academic-spin-off sourcing model.
  • coparion: Cologne-based German VC investing Seed-to-Series A in technology-enabled and life sciences startups. Co-invested with OCCIDENT in Tubulis Series B, sharing similar initial ticket sizes and DACH focus.
  • Bayern Kapital: Bavarian state-backed VC fund providing Seed to later-stage capital to technology and life sciences startups in the OCCIDENT home region. Existing co-investor in Tubulis Series C rounds.
  • Forbion: Leading European life sciences specialist VC with deep biotech focus across multiple therapeutic areas. Comparable in thesis (science-driven biotech investing) but operates at significantly larger AUM.
  • xista science ventures: Austrian-based deep tech and science-focused VC co-organizing pitch events with OCCIDENT. Closest scale and thesis match — both focus on academic spin-offs in DACH.
  • BioMedPartners: Swiss/German-based VC investing in life sciences and biotech companies. Co-invested with OCCIDENT in Tubulis Series B — comparable academic-spin-out pipeline and DACH geography.

Broad incumbents

  • Andera Partners: Paris-based private equity and venture investor with a sizeable European life sciences franchise. Led Tubulis Series B (€60M) — directly overlapping OCCIDENT in life sciences deal underwriting at scale.
  • EQT Life Sciences: Pan-European life sciences investor (formerly LSP), writing Series A through growth cheques. Co-invested with OCCIDENT in Tubulis Series C, overlapping in late-stage biotech deal participation.
  • Seventure Partners: Paris-based European VC with strong life sciences/healthcare franchise. Co-investor in Tubulis Series C, comparable in cross-stage European biotech investing but with larger fund management structure.
  • Evotec: Large drug-discovery and development platform with an active VC/strategic partnership arm. Co-invested in Tubulis Series B and directly overlaps with OCCIDENT portfolio in early-stage biotech deal participation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

OCCIDENT social profiles

Digital presence

OCCIDENT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OCCIDENT leadership team

Management profile

Number of profiles

Profiles4 records

OCCIDENT funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OCCIDENT M&A and investment

M&A and investment

M&A

Investments38 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OCCIDENT

What does OCCIDENT do?

OCCIDENT is an owner-managed venture capital firm that invests its own capital into deep-tech startups, beginning at the Seed financing round and continuing with follow-on investments through Series A and later rounds. The firm focuses on scientific research spin-offs across life sciences (Biotech, Pharma, Diagnostics, MedTech, HealthTech, Veterinary Medicine, Chemistry, FoodTech, Industrial Biotech) and industrial tech (semiconductors, sensors, advanced materials). In addition to capital, OCCIDENT provides active portfolio management and acts as a long-term partner to founders, leveraging its OCCIDENT@ACADEMIA program for deal sourcing.

Is OCCIDENT a public or private company?

OCCIDENT is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OCCIDENT founded?

OCCIDENT was founded in 2012. It employs 1 to 10 people.

Where is OCCIDENT based?

OCCIDENT is headquartered in München, Germany, in the Europe region.

How does OCCIDENT make money?

One revenue line is on record: venture Capital Returns.

Who are OCCIDENT's main competitors?

Direct peers on record are High-Tech Gründerfonds (HTGF), coparion, Bayern Kapital, Forbion, xista science ventures and BioMedPartners. Broad incumbents are Andera Partners, EQT Life Sciences, Seventure Partners and Evotec.

Does OCCIDENT have an API?

No public API is recorded for OCCIDENT.

What industry is OCCIDENT in?

OCCIDENT's product category is Venture Capital. Its primary akta.pro industry code is FSANAHAL, Corporate Deep Tech / R&D Commercialization CVC. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EleconomistaOccident y CRB Health Tech entran en el capital de la catalana EholoSpanish venture capital firm GCO Ventures and CRB Health Tech's health fund have entered the shareholding of Eholo, a Catalan company that manages mental health consultations and clinics. The investment amount was not disclosed, with funds earmarked for its AI assistant MIA, data security, and strategic agreements. Eholo serves 21,000 mental health professionals and handled over a million psychology sessions last year.European BiotechnologyImmitra Bio raises CHF 2.4M for in-vivo gene editingImmitra Bio raised CHF 2.4M in a round led by Backbone Ventures for its in-vivo gene-editing technology. The funds will support preclinical proof-of-concept studies for IB-003, a potential one-time treatment for an inherited anemia. The company has not disclosed the specific disease, molecular target, or development timeline.VenturelabImmitra Bio raises CHF 2.4 million to advance in-vivo gene editing platform – VenturelabGeneva-based Immitra Bio raised CHF 2.4 million in pre-seed funding to advance its in-vivo gene editing platform and lead candidate IB-003. The round, led by Backbone Ventures, will fund preclinical proof-of-concept studies and pipeline expansion. The company aims to deliver off-the-shelf treatments for inherited anemia.BioAlpsImmitra Bio Closed a CHF 2.4 Million Pre-Seed Financing RoundImmitra Bio, an ETHZ spinoff, closed a CHF 2.4 million pre-seed round led by Backbone Ventures. The funds will support preclinical studies for its lead candidate IB-003, a one-time curative gene editing treatment for inherited anemia. The company aims to make gene editing therapies scalable and accessible.startupticker.chImmitraBio secures CHF 2.4 million in pre-seed fundingImmitra Bio, a Geneva-based biotech company, completed an upsized CHF 2.4 million pre-seed financing round to advance its scalable in-vivo gene editing platform and lead candidate IB-003, a potential one-time curative treatment for an inherited anemia. The round was led by Backbone Ventures and co-led by OCCIDENT, with participation from Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation, and select private investors. Proceeds will support preclinical proof-of-concept studies for IB-003 and further pipeline discovery enabled by the company's digital target discovery platform.Empresas de Capital Riesgo en EspaCRB Health Tech closes its Digital Health Tech III fund at €50 millionCRB Health Tech closed its Digital Health Tech III fund at €50 million, exceeding its initial €30 million target. The fund has made ten investments across Europe, with about half in Spain, and plans to build a portfolio of roughly 25 companies.InvestorsinhealthcareGermany: Gilead significantly expanding ADC capabilities with agreement to acquire Tubulis for up to US$5bnGilead Sciences agreed to acquire Germany-based Tubulis for a total deal value of up to US$5bn. The acquisition would give Gilead access to Tubulis's ADC capabilities. The terms of the deal were not disclosed.startupticker.chCHF 7.25 million for a platform reducing the burden of sepsisHemotune AG has closed a CHF 7.25 million Series B1 funding round to advance the preclinical development of its HemoSystem blood purification platform for sepsis treatment. The investment, led by OCCIDENT with participation from existing and new investors including Zürcher Kantonalbank and HEMEX, will support the preparation of clinical trials for the technology.Nordic 9Hemotune AG raised CHF 5.1 million Series A in a round led by OccidentHemotune AG raised CHF 5.1 million in a Series A led by Occident, with Greencross Medical Science and Zürcher Kantonalbank participating. The round brings total funding to over CHF 10 million, to be used for preclinical development of its HemoSystem blood purification platform.UnquoteBayern Kapital, HTGF, Occident exit CunesoftBayern Kapital, HTGF, and Occident sold their stakes in Cunesoft to Phlexglobal, a Virtuvian Partners portfolio company. Cunesoft, a pharmaceutical software provider, had raised funds in 2014 and 2016 for international expansion. Phlexglobal produces trial master file management software and employs 300 staff.